id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9723 R34622 |
Huber-Mollema (Carbamazepine), 2019 | ADHD total (Social Emotional Questionnaire) (Completed by mothers) Clinical cutoff | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.47 [0.05;4.16] C | 1/36 5/87 | 6 | 36 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9734 R34679 |
Richards (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
0.86 [0.45;1.67] excluded (control group) |
17/201 13/149 | 30 | 201 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9735 R34689 |
Richards (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.83 [1.11;3.02] | 17/201 11,841/286,966 | 11,858 | 201 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9711 R34564 |
Cohen (Carbamazepine), 2013 | Children with either ADHD inattentive OR combined types > 1 SD (from the Attention Problems and Hyperactivity scales of the BASC) (Parent) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.61 [0.56;4.69] C | 9/52 7/61 | 16 | 52 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9743 R34757 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.94 [0.15;6.00] C excluded (control group) |
2/31 3/44 | 5 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9745 R34776 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
2.00 [0.50;8.60] excluded (control group) |
2/31 1,743/43,571 | 1,745 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9746 R34790 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.59 [0.45;14.78] C | 2/31 4/154 | 6 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9747 R34807 |
Viinikainen (Carbamazepine) b, 2006 | Conners' Teacher Rating Scale Global Index scores >1 SD | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.15 [0.01;3.50] C | 0/12 2/11 | 2 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.66 [1.08;2.54] | 11,888 | 332 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, NOS) (Indications NOS; 3: Carbamazepine; 4: Carbamazepine) (Controls unexposed, sick) ; 5: Carbamazepine) ;
Asymetry test p-value = 0.1822 (by Egger's regression)
slope=0.9374 (0.3047); intercept=-1.0841 (0.6270); t=1.7290; p=0.1822
excluded 9743, 9745, 9734